Regenics has launched development of a novel marine based biotechnolgy derived treatment for severe wound debridement WoundClear™.

WoundClear™ is an novel enzymatic debridement treatment developed as a drug (BLA =Biologics Licence Application in the US and a biologics drug application for EMEA review in Europe.

The treatment is exploratory pre-clincial phase. 

The intended use for WoundClear™ is assumed to be:

  • Partial and full-thickness wounds with eschar development indicated for enzymatic treatment of severe wounds in conjunction with or as stand alone debridement therapy
  • Trauma wounds (abrasions, lacerations, second-degree burns, skin tears)
  • Pressure ulcers
  • Chronic vascular ulcers
  • Diabetic ulcers

WoundClear™ is protected by global patents in US, EU and RoW 

More info on WoundClear™ will be made soon:

 

Regenics AS has developed a number of assays and techniques to study effects of various substances on skin cells both in vitroin vivo and in the clinic. Our focus is to develop products and techniques for therapeutic skin applications and to improve skin appearance.